Pricing Log in Create free account

Rapport Therapeutics, Inc. (RAPP) vs Ultragenyx Pharmaceutical Inc. (RARE)

Rapport Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. Rapport Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. are of similar size ($1.5B and $1.4B). Rapport Therapeutics, Inc. has the higher net margin (0.00% vs −81.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 10 metrics below, Rapport Therapeutics, Inc. leads on 8 and Ultragenyx Pharmaceutical Inc. on 2.

Valuation

Metric RAPP RARE Biotechnology median
P/E n/m n/m 8.50
P/S n/m 2.07 9.71
P/B 3.09 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 1.66 9.21
Earnings yield (11.03%) (40.17%) (33.15%)
Free cash flow yield (7.41%) (33.34%) (25.50%)

Profitability

Metric RAPP RARE Biotechnology median
Gross margin — 83.12% 65.16%
Operating margin 0.00% (73.64%) 0.00%
Net margin 0.00% (81.73%) 0.00%
Free cash flow margin 0.00% (68.90%) 0.00%
Return on equity (39.96%) 838.86% (56.36%)
Return on assets (36.85%) (45.60%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric RAPP RARE Biotechnology median
Revenue growth (TTM) — 17.51% 6.02%
EPS growth (last fiscal year) 24.34% 7.31% 30.26%
Revenue growth, 5-year CAGR — 19.95% 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric RAPP RARE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 15.72 1.73 4.72
Net debt to EBITDA 3.91 1.35 0.96

Dividend

Metric RAPP RARE Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric RAPP RARE Biotechnology median
Market cap 1.42b 1.50b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack